Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05753189 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
A Phase 3 study of Presbyopia and Eye Diseases, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 362
- Enrollment target
- 20
- Study locations
NCT05753189 is a Phase 3 study of Presbyopia and Eye Diseases that has completed, run by LENZ Therapeutics. The registered enrollment target is 362 participants, above the 261-participant average among 38 other Presbyopia trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT05753189, a Phase 3 study of Presbyopia and Eye Diseases, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 362 participants
- Enrollment target
- 20
- Study locations
Study Summary
Safety Study of the Long-Term Safety of LNZ101 in Presbyopic Subjects
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aceclidine+Brimonidine combination ophthalmic solution
- DRUG Aceclidine Ophthalmic Solution
Study Locations (20)
California
- Site #303 - Garden Grove
- Site #313 - Glendale
- Site #334 - La Jolla
- Site #322 - Newport Beach
- Site #306 - Petaluma
- Site #337 - Rancho Cordova
- Site #304 - Santa Barbara
Arizona
- Site #302 - Chandler
- Site #320 - Mesa
- Site #321 - Phoenix
- Site #328 - Phoenix
- Site #338 - Scottsdale
- Site #331 - Sun City
Florida
- Site #319 - Crystal River
- Site #309 - Mt. Dora
Alabama
- Site #326 - Dothan
Colorado
- Site #308 - Littleton
Connecticut
- Site #316 - Danbury
Illinois
- Site #317 - Rock Island
Kansas
- Site #301 - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2024-02-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05753189
The ClinicalTrials.gov registry entry for NCT05753189 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 261-participant average among 38 other Presbyopia trials with a reported enrollment target (39% higher). The listed sponsor is LENZ Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Presbyopia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05753189 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05753189 about?
NCT05753189 is a clinical study titled "Phase 3 Safety Study for the Treatment of Presbyopia Subjects". Safety Study of the Long-Term Safety of LNZ101 in Presbyopic Subjects
What is the current status of trial NCT05753189?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 362 participants. The study started on 2023-02-21. Estimated completion is 2024-02-09.
What conditions does trial NCT05753189 study?
This clinical trial studies the following conditions: Presbyopia, Eye Diseases, Near Vision, Miosis.
What interventions are being tested in trial NCT05753189?
The interventions under investigation include: Placebo (DRUG), Aceclidine+Brimonidine combination ophthalmic solution (DRUG), Aceclidine Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05753189?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05753189 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase III Presbyopia Correction Using the VIS Opti-K™ System
RECRUITING · Phase 3
-
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
COMPLETED · Phase 3
-
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
COMPLETED · Phase 3
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.